Application of microcystic toxins-LR in preparation of medicines for preventing and treating pulmonary fibrosis

Abstract

The invention relates to medicinal application of microcystic toxins-LR, in particular to application of the microcystic toxins-LR in preparation of medicines for preventing and treating pulmonary fibrosis, belonging to the technical field of medicines. The microcystic toxins-LR is proved to be capable of improving the state of pulmonary fibrosis caused by bleomycin. The microcystic toxins-LR can inhibit the mRNA expression rise, caused by the bleomycin, of pulmonary fibrosis-related molecules such as transforming growth factor (TGF)-beta, tumor necrosis factor (TNF)-alpha, IL-1beta, IL-6, NF-kB and ET-1. The microcystic toxins-LR can inhibit the mRNA expression rise, caused by the bleomycin, of lung tissue vascular endothelial growth factor (VEGF). The microcystic toxins-LR interferes and relieves rat pulmonary fibrosis, induced by the bleomycin, by using ways such as a TGF-beta / Smad pathway and angiogenesis inhibition. A new way is provided for preparing the medicines for preventing and / or treating the pulmonary fibrosis disease.

Description

technical field [0001] The invention relates to the medical application of microcystin-LR, especially the application of microcystin-LR in the preparation of medicines for preventing and treating pulmonary fibrosis, which belongs to the technical field of medicine. Background technique [0002] Pulmonary fibrosis (PF) is a severe chronic lung interstitial disease caused by various reasons. According to the etiology, it can be divided into secondary pulmonary fibrosis (SPF) and idiopathic pulmonary fibrosis (IPF). The etiology of the former is clear, and representative diseases include pneumoconiosis, silicosis, asbestosis, and pulmonary fibrosis related to autoimmune diseases, etc.; the etiology of the latter is not clear, and it is a common lung disease that currently lacks clinical intervention. As a chronic inflammatory interstitial lung disease, IPF is mainly manifested by the appearance of fibroblast foci, a large amount of extracellular matrix (ECM) deposition, and co...

AI Technical Summary

Problems solved by technology

Our early research found that when mice were exposed to MC-LR by drinking water for 12 months, only inflammation occurred in the lungs of the mice, but no pulmonary fibrosis occurred, indicating that MC-LR may have an anti-fibrosis effect, but so far , there is no research on the biological activity or clinical application of microcystin-LR against pulmonary fibrosis

Images